Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Next Previous
Trial Profile

Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Cladribine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Mitoxantrone
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation

Most Recent Events

  • 12 Dec 2023 Results (n=773 ) Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022,presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 06 Jun 2023 Results(n=650) assessing the effect of the pandemic on managing pts with AML in the Connect Myeloid Registry presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 13 Dec 2022 Results (n=570; as of 18 Feb 2022) assessing impact of different therapies on lifestyle disruptions in patients with LR-MDS presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top